Angiotensin-converting enzyme inhibitor-induced angioedema: epidemiology, pathogenesis and management

Česká verzia

Authors: Marta Sobotková
Authors place of work: Ústav imunologie 2. LF UK a FN Motol, Praha
Published in the journal: Vnitř Lék 2018; 64(10): 928-933
Category:

Summary

Angiotensin-converting enzyme-induced angioedema occurs in 0.1–0.7 % of recipients. Swelling often affects head and neck and makes it an extremely dangerous adverse effect. Bradykinin is considered to be the main mediator of edema in these cases. There is currently no specific treatment for angioedema of this etiology. Drugs used for treatment of attacks in hereditary angioedema with C1 inhibitor deficiency are tried also in this indication, but there are currently no clinical studies available supporting their effectiveness. Patients using angiotensin-converting enzyme inhibitors with angioedemas of unknown etiology must discontinue using this drug. Swelling episodes may appear even after this arrangement.

Key words:

angioedema – angiotensin-converting enzyme inhibitors – bradykinin

Zdroje

Izzo JL Jr, Weir MR. Angiotensin-converting enzyme inhibitors. J Clin Hypertens (Greenwich) 2011; 13(9): 667–675. Dostupné z DOI: <http://dx.doi.org/10.1111/j.1751–7176.2011.00508.x>.
Bas M, Greve J, Strassen U et al. Angioedema induced by cardiovascular drugs: new players join old friends. Allergy 2015; 70(10): 1196–1200. Dostupné z DOI: <http://dx.doi.org/10.1111/all.12680>.
Yusuf S, Teo K, Anderson C et al. [Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (TRANSCEND) Investigators]. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet 2008; 372(9644): 1174–1183. Dostupné z DOI: <http://dx.doi.org/10.1016/S0140–6736(08)61242–8>. Erratum in Lancet.2008; 372(9647): 1384.
Cicardi M, Suffritti C, Perego F et al. Novelties in the Diagnosis and Treatment of Angioedema. J Investig Allergol Clin Immunol 2016; 26: 212–221; quiz two pages after page 221. Dostupné z DOI: <http://dx.doi.org/10.18176/jiaci.0087>
Cicardi M, Aberer W, Banerji A et al. Classification, diagnosis, and approach to treatment for angioedema: consensus report from the Hereditary Angioedema International Working Group. Allergy 2014; 69(5): 602–616. Dostupné z DOI: <http://dx.doi.org/10.1111/all.12380>.
Brown T, Gonzalez J, Monteleone C. Angiotensin-converting enzyme inhibitor-induced angioedema: A review of the literature. J Clin Hypertens (Greenwich) 2017; 19(12): 1377–1382. Dostupné z DOI: <http://dx.doi.org/10.1111/jch.13097>.
Hakl R. Současné možnosti léčby hereditárního angioedému. Vnitř Lék 2016; 62(9): 736–739.
Zuraw BL The Pathophysiology of Hereditary Angioedema. World Allergy Organ J 2010; 3(9 Suppl): S25-S28. Dostupné z DOI: <http://dx.doi.org/10.1097/WOX.0b013e3181f3f21c>.
Guyer ACH, Banejri A. ACE inhibitor-induced angioedema. Dostupné z WWW: <https://www.uptodate.com/contents/ace-inhibitor-induced-angioedema>.
Banerji A, Blumenthal KG, Lai KH et al. Epidemiology of ACE Inhibitor Angioedema Utilizing a Large Electronic Health Record. J Allergy Clin Immunol Pract 2017; 5(3): 744–749. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jaip.2017.02.018>.
Hahn J, Trainotti S, Hoffmann TK et al. Drug-Induced Inhibition of Angiotensin Converting Enzyme and Dipeptidyl Peptidase 4 Results in Nearly Therapy Resistant Bradykinin Induced Angioedema: A Case Report. Am J Case Rep 2017; 18: 576–579.
Kostis JB, Packer M, Black HR et al. Omapatrilat and enalapril in patients with hypertension: the Omapatrilat Cardiovascular Treatment vs Enalapril (OCTAVE) trial. Am J Hypertens 2004; 17(2): 103–111.
Morimoto T, Gandhi TK, Fiskio JM et al. An evaluation of risk factors for adverse drug events associated with angiotensin-converting enzyme inhibitors. J Eval Clin Pract 2004; 10(4): 499–509. Dostupné z DOI: <http://dx.doi.org/10.1111/j.1365–2753.2003.00484.x>.
Brown NJ, Ray WA, Snowden M et al. Black Americans have an increased rate of angiotensin converting enzyme inhibitor-associated angioedema. Clin Pharmacol Ther 1996; 60(1): 8–13. Dostupné z DOI: <http://dx.doi.org/10.1016/S0009–9236(96)90161–7>.
Kostis JB, Kim HJ, Rusnak J et al. Incidence and characteristics of angioedema associated with enalapril. Arch Intern Med 2005; 165(14): 1637–1642. Dostupné z DOI: <http://dx.doi.org/10.1001/archinte.165.14.1637>.
Byrd JB, Woodard-Grice A, Stone E et al. Association of angiotensin-converting enzyme inhibitor-associated angioede ma with transplant and immunosuppressant use. Allergy 2010; 65(11): 1381–1387. Dostupné z DOI: <http://dx.doi.org/10.1111/j.1398–9995.2010.02398.x>.
Bernstein JA, Cremonesi P, Hoffmann TK et al. Angioedema in the emergency department: a practical guide to differential diagnosis and management. Int J Emerg Med 2017; 10(1): 15. Dostupné z DOI: <http://dx.doi.org/10.1186/s12245–017–0141-z>.
Kalambay J, Ghazanfar H, Martes Pena KA et al. Pathogenesis of Drug Induced Non-Allergic Angioedema: A Review of Unusual Etiologies. Cureus 2017; 9(8): e1598. Dostupné z DOI: <http://dx.doi.org/10.7759/cureus.1598>.
Liška M. Vyšetřovací metody v alergologii. Postgraduální medicína 2012; 14(2): 122–128.
Sobotková M. Současné možnosti léčby hereditárního angioedému. Farmakoterapeutická revue 2017; 3: 155–160.
Baş M, Greve J, Stelter K et al. A Randomized Trial of Icatibant in ACE-Inhibitor-Induced Angioedema. N Engl J Med 2015; 372(5): 418–425. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1312524>.
Straka BT, Ramirez CE, Byrd JB et al. Effect of bradykinin receptor antagonism on ACE inhibitor-associated angioedema. J Allergy Clin Immunol 2017; 140(1): 242–248. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jaci.2016.09.051>.
Sinert R, Levy P, Bernstein JA et al. Randomized Trial of Icatibant for Angiotensin-Converting Enzyme Inhibitor-Induced Upper Airway Angioedema. J Allergy Clin Immunol Pract 2017; 5: 1402–1409.e3. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jaip.2017.03.003>.
Greve J, Bas M, Hoffmann TK et al. Effect of C1-Esterase-inhibitor in angiotensin-converting enzyme inhibitor-induced angioedema. Laryngoscope 2015; 125(6): E198-E202. Dostupné z DOI: <http://dx.doi.org/10.1002/lary.25113>.
Bernstein JA, Moellman JJ, Collins SP et al. Effectiveness of ecallantide in treating angiotensin-converting enzyme inhibitor-induced angioedema in the emergency department. Ann Allergy Asthma Immunol 2015; 114(3): 245–249. Dostupné z DOI: <http://dx.doi.org/10.1016/j.anai.2014.12.007>.
Lewis LM, Graffeo C, Crosley P et al. Ecallantide for the acute treatment of angiotensin-converting enzyme inhibitor-induced angioedema: a multicenter, randomized, controlled trial. Ann Emerg Med 2015; 65(2): 204–213. Dostupné z DOI: <http://dx.doi.org/10.1016/j.annemergmed.2014.07.014>.
Beltrami L, Zanichelli A, Zingale L et al. Long-term follow-up of 111 patients with angiotensin-converting enzyme inhibitor-related angioedema. J Hypertens 2011; 29(11): 2273–2277. Dostupné z DOI: <http://dx.doi.org/10.1097/HJH.0b013e32834b4b9b>.
Makani H, Messerli FH, Romero J et al. Meta-analysis of randomized trials of angioedema as an adverse event of renin-angiotensin system inhibitors. Am J Cardiol 2012; 110(3): 383–391. Dostupné z DOI: <http://dx.doi.org/10.1016/j.amjcard.2012.03.034>.
Anzaldua DA, Schmitz PG. Aliskiren as an alternative in a patient with life-threatening ACE inhibitor-induced angioedema. Am J Kidney Dis 2008; 51(3): 532–533. Dostupné z DOI: <http://dx.doi.org/10.1053/j.ajkd.2007.11.035>.
Bork K, Wulff K, Steinmüller-Magin L et al. Hereditary angioedema with a mutation in the plasminogen gene. Allergy 2018; 73(2): 442–450. Dostupné z DOI: <http://dx.doi.org/10.1111/all.13270>.
Bafunno V, Firinu D, D‘Apolito M et al. Mutation of the angiopoietin-1 gene (ANGPT1) associates with a new type of hereditary angioedema. J Allergy Clin Immunol 2018; 141(3): 1009–1017. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jaci.2017.05.020>.